I agree with all that. That’s why I still have this on my radar. However, the ‘amount’ of the debt is already substantial for a drug that has barely even been tested. And, those tests were for reactions to the injection, not the efficacy, of the drug on three people no less.
My hopes for Prolanta being effective are very limited. Time will tell, though.
Good luck
My posts are of my opinion and should not be taken as solid trading advice. I do not have a vision of the future. I follow trends and base my decisions on that alone.